tradingkey.logo

Berenberg raises AbbVie PT on higher immunology drug sales

ReutersMar 12, 2025 10:49 AM

** Berenberg raises PT on drugmaker AbbVie ABBV.N to $195 from $165, citing higher immunology drug sales

** New PT is a 8.7% downside to stock's last close

** Brokerage says AbbVie knows the autoimmune market well

** Says co reduced exposure to antirheumatic drug Humira and bolstered cash flows through acquisition of Allergan

** "We now forecast $36 bln peak sales for Skyrizi to give an NPV of $60/share (32% of total)," says brokerage

** Skyrizi is used to treat psoriasis and other inflammatory conditions

** Nineteen of 27 brokerages rate stock "buy" or higher, and 8 "hold; median PT is $215 - data compiled by LSEG

** ABBV up 20.2% YTD as of last close; up ~15% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.